VALN Valneva Vaccines: רווח למניה לשנה מתגלגלת

Strict temperature logistics for pharmaceuticals dictate high delivery costs, as confirmed by the annual EPS (TTM) growth statistics on the GURU.Markets chart, where the value -135.10 describes the current level. Valneva SE (VALN) fundamentals rely on the unique IXCHIQ vaccine and a partnership with Pfizer. Furthermore, the business is based on stable demand, which renders the asset a defensive asset during recessionary periods.

For Valneva SE (VALN), the earnings per share trend reflects the operational efficiency of its own sterile manufacturing capacities in Europe and the stability of vaccine supplies. By analyzing the 12-month YoY EPS history, an investor assesses the rolling annual net income growth rate, which helps identify market imbalances and avoid purchasing the asset at a local valuation peak.